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Abstract
Unfractionated heparin (UFH) and low molecular heparin derivatives (LMWH) display
numerous biological properties in addition to their anticoagulant effects. However, due
to the physicochemical heterogeneity of these drugs, a better understanding concerning
their effects on human cells is clearly needed. Considering that heparins are mainly
excreted by the kidney, we focused our attention on the effect of UFH and LMWH on
human podocytes by functional and morphological/phenotypic in vitro analyses. We
demonstrated that these products differentially modulate the permeability of podocyte
monolayer to albumin. The functional perturbations observed were correlated to
significant cellular morphological and cytoskeletal changes, as well as a decrease in the
expression of proteins involved in podocyte adherence to the extracellular matrix or
intercellular interactions. This point confirms that UFH and the different LMWHs exert
specific effects on podocyte permeability and underlines the need of in vitro tests to
evaluate new biological nonanticoagulant properties of LMWH.
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1 | INTRODUCTION
Unfractioned heparin (UFH) and its low molecular weight
derivatives (LMWH) are widely used for the prevention and the
treatment of venous thromboembolic events (Gray, Hogwood, &
Mulloy, 2012). Heparins are heterogeneous glycosaminoglycans
composed of a mixture of polysulfated chains comprised of
alternating disaccharide residues of D‐glucosamine and uronic
acid residues linked by glycosidic bonds. Low molecular weight
heparins (2–8 kDa) are issued from UFH (14 kDa) by chemical or
enzymatic depolymerisation and possess different anticoagulant
properties. In addition to their different polysaccharide size
distribution, the structural variations could explain the different
anticoagulant profiles of LMWH. These molecules show con-
siderable variations in their pharmacokinetic and pharmacody-
namic effect, arguing in favour of noninterchangeability of
LMWH as recommended by the Food and Drug Administration
(Fareed et al., 2004). In addition to these anticoagulant proper-
ties, LMWHs display numerous other biological activities such as
anti‐inflammatory, antiangiogenic or antimetastatic properties
(Yan et al., 2017).
UFH and derivatives are mainly excreted by the kidney.
Numerous studies have been performed in chronic kidney disease
(CKD) patients, allowing the establishment of specific posology
and LMWH choice as a function of kidney filtration capacity
(Sciascia et al., 2017). UFH is able to limit glomerular function
deficiency in glomerulonephritis through multiple mechanisms
involving an effect on growth factors, an inhibition of heparinase,
or by attenuating the inflammatory status (Gambaro & Kong,
2010; Gambaro et al., 1992). Accordingly, sulodexide (a hetero-
geneous group of sulfated glycosaminoglycans) has demonstrated
a beneficial impact on the proteinuria observed in diabetic
patients; even its efficacy is still debated (Li et al., 2015; Olde
Engberink, & Vogt, 2016). In contrast to the curative or
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renoprotective effects of heparins, little is known about their
effects on healthy kidney. In vitro studies have demonstrated
that heparin could enhance specific gene expression in isolated
rat podocytes (Yaoita et al., 2014); but up to now, there is no
functional study analysing the effects of UFH or LMWH on the
human kidney. The constant development of new pharmacologi-
cal compounds, and in particular heparin derivatives, needs
functional tests to be able to predict their effects on kidney
function (Tiong et al., 2014).
Kidney glomerular filtration involves endothelial cells, glomerular
basement membrane, and podocytes. Podocytes are terminally
differentiated epithelial cells that display elongated interdigitating
foot processes that form a zipper‐like network allowing filtration.
Specific interactions between cells, named slit diaphragms, form the
ultimate filtration barrier which prevent the passage of macromole-
cules larger than serum albumin (Garg, 2018). Among the numerous
proteins that are involved in the slit diaphragm, nephrin and ZO‐1
play an important role in the maintenance of this particular structure.
Besides these specialised intercellular complexes, podocytes must
efficiently adhere to the basal membrane. At a molecular level, cell–
matrix interactions involve podocyte adhesion receptors, such as
integrins (and notably the main integrin α3β1), that are intimately
coupled to cell cytoskeleton (Sever & Schiffer, 2018). This podocyte
spatial organisation is crucial for the maintenance of an efficient
glomerular filtration. These properties identify the podocyte as a
“weak link” in numerous pathologies such as diabetes mellitus (Dai,
Liu, & Liu, 2017), lupus nephritis (Chen & Hu, 2017) or focal
segmental glomerulosclerosis (FSG), as well as a sensitive target for
potential nephrotoxic drugs.
Based on these considerations and previous results, we studied
the effects of commercially available UFH and LMWH on podocytes.
Considering that the podocyte is a sensitive target cell involved in
glomerular filtration, we focused on this cell using an in vitro assay
allowing the measurement of albumin permeability through a human
podocyte monolayer. The goal of this study was to investigate the
effect of heparin and its derivatives on podocyte permeability by
functional tests combined with morphological/phenotypic analysis
after drug exposure. Our in vitro approach has also been carried out
to highlight new properties of heparins regardless of their antic-
oagulant capacities.
2 | MATERIALS AND METHODS
Except when specified, all the reagents were purchased from Sigma‐
Aldrich (Saint‐Quentin Fallavier, France). UFH (Heparine sodique®;
Panpharma SA, Luitré, France); the LMWH enoxaparin (Lovenox®;
Sanofi Aventis, Lyon, France); tinzaparin (Innohep®; Leo Pharma,
Voisins‐le‐bretonneux, France); and the direct oral anticoagulants
dabigatran (Pradaxa®; Boehringer Ingelheim, Paris, France), rivarox-
aban (Xarelto®; Bayer HealthCare SAS, Lyon, France) and argatroban
(Arganova®; LFB Biomedicaments, Courtaboeuf, France) were all
obtained in their commercial forms.
2.1 | Cell culture
Human podocytes, kindly provided by Saleem et al. (2002), were
routinely cultured in RPMI‐1640 medium containing 10% foetal
bovine serum, 1% insulin–transferrin–selenium‐A supplement,
and 1% penicillin–streptomycin solution as previously described
(Delézay et al., 2017). The cells were cultured at 33°C with
95% air and 5% CO2 in 75 cm
2 flasks (BD Falcon; Le Pont de Claix,
France). To obtain fully differentiated podocytes, the cells were
switched to a 37°C incubator (5% CO2) and cultured in the same
medium for 12–14 d before use. For cultures on permeable
supports, undifferentiated cells (grown at 33°C) were seeded at a
density of 2.5 × 105 cell/filter (BD‐Falcon cell culture inserts,
24‐well size, 3‐μm pore size), cultured 24 hr at 33°C for cell
adhesion and then switched to 37°C for 12–14 d. The medium
was changed twice a week.
2.2 | Evaluation of cell toxicity
Podocytes were seeded in 96‐well plates at a density of 100,000
cells/well and allowed to differentiate at 37°C for 12 d. Then the cells
were treated with different concentrations of each molecule during
2 d. Following incubation, cytotoxicity of the tested compounds was
evaluated by both LDH and XTT assays. LDH release in cell
supernatant was quantified using the CytoTox‐ONE™ Homogeneous
Membrane Integrity Assay (Promega, Madison, WI) and the XTT
assay was performed using the In Vitro Toxicology Assay Kit, XTT
based according to the manufacturer’s instructions. Each condition
was performed in quadruplicate (n = 4).
2.3 | Evaluation of podocyte monolayer
permeability
The experiments were performed on differentiated podocytes
grown on permeable supports (BD‐Falcon cell culture inserts,
24‐well size, 3‐μm pore size) treated or not for 48 hr with
increasing concentrations of UFH, enoxaparin, tinzaparin, fonda-
parinux, argatroban, rivaroxaban or dabigatran in the two
compartments (apical and basal). Each assay was performed in
quadruplicate (n = 4) with a positive control (puromycin amino-
nucleoside [PAN], 40 µg/ml) to verify podocyte response to drug
injury. Podocyte monolayer permeability was determined in the
basal to apical direction.
Cells were first incubated for 1 hr at 37°C in serum‐free RPMI
medium (SF‐RPMI) and then incubated with fluorescein isothiocya-
nate‐bovine serum albumin (FITC‐BSA) at a concentration of 0.5 g/L
in the basal compartment (1 ml). After an incubation of 4 hr at 37°C,
100 μl was taken from the apical compartment, transferred into a
96‐well plate and fluorescence was measured using a fluorimeter
(Exc = 485 nm, Em = 538 nm; Fluoroskan Ascent; Thermo Fisher
Scientific, Dardilly, France).
The apparent permeability of albumin was calculated with the
following formula:
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where Papp is the apparent permeability, Vr is the volume of medium
solution in the receiving chamber, C0 is the initial concentration of
drug in the basal compartment, S is the area of the monolayer, C2 is
the concentration of the drug found in the apical compartment after
an incubation of 4 hr, and t is the incubation time.
2.4 | Morphological/phenotypic analysis by
immunofluorescence experiments
Immunofluorescence experiments were performed with phalloidin‐
iFluor 555 (Abcam, Cambridge, UK) and 4′,6‐diamidine‐2′‐phenylindole
dihydrochloride (DAPI; Life Technologies, Carlsbad, CA) to visualise cell
cytoskeleton and nucleus, respectively. Monoclonal antibodies directed
against ZO‐1 (BD Bioscience, Le Pont de Claix, France) or against the
integrin α3β1 (Dako, les Ulis, France) were used to show intercellular
contacts and cell‐support interactions, respectively. Differentiated
podocytes grown on glass coverslips were fixed with a 4% paraformal-
dehyde solution for 20min, permeabilised with 0.2% Triton X‐100
(20min). After two washes with phosphate‐buffered saline (PBS), the
cells were incubated with primary antibodies (1/50) for 1 hr at room
temperature, washed and incubated with the anti‐mouse Alexa Fluor
488 conjugated secondary antibodies (1/200; Thermo Fisher Scientific,
Illkirch, France). The images were acquired using an epifluorescence
inverted microscope (IX81; Olympus, Tokyo, Japan) equipped with a cell
imaging software (SoftImaging System GmbH, Munster, Germany).
2.5 | Cell surface measurements
Podocytes were seeded on a 24‐well plate and cultured for 12 days at
37°C to obtain fully differentiated cells. The cells were treated or not
with PAN (40 µg/ml) or UFH (200UI/ml) for 48 hr. Live cells were rinsed
with RPMI complete medium and then incubated with the same
medium containing 2 µM of calcein acetoxymethyl (Calcein‐AM;
Interchim, Montluçon, France) and 8 µM of Hoechst 33342 (Sigma-
Aldrich, Saint‐Quentin Fallavier, France) for 45min at room tempera-
ture. After two rinses, the wells were observed with an epifluorescence
inverted microscope (IX81; Olympus) allowing the observation of the
entire well by using a FITC filter for observing calcein‐AM labelling, or a
DAPI filter for observing Hoechst 33342 labelling.
For the quantitative analysis of cellular parameters, 12 images
(three images by well, four wells for each condition) were captured
and analysed using the ImageJ software (Rueden et al. 2017) using
a protocole adapted from the article by Kachurina et al. (2016).
Briefly, the cell number was determined by counting Hoechst
33342‐labelled cell nucleus (blue channel) using the “analyse
particles” function on ImageJ software after an automatic thresh-
old (default). For the quantification of the total cell surface, the
scale was converted in µm (using the scale bar) and a bandpass
filter was applied on each image (green channel) to homogenise
the fluorescent labelling. The same automatic threshold (MinError)
was applied on each picture allowing the measurement of the total
cell surface using the appropriate ImageJ software function (area
measurement). The value obtained for each image was divided by
the number of cells counted in the same field observed to obtain
an average individual cell surface.
2.6 | Cell detachment assay
Differentiated podocytes grown on 96‐well plate were incubated
with or without PAN (40 µg/ml) or heparin (200 UI/ml) or
enoxaparin (200 UI/ml) or tinzaparin (200 UI/ml) for 48 hr. Eight
wells of untreated cells were rapidly fixed with 4% paraformalde-
hyde solution for 20 min (positive control of cell adhesion, 0%
detachment) and eight wells were incubated 10 min with trypsin
(negative control of cell adhesion, 100% detachment). Experi-
mental wells were washed three times with PBS before to be fixed
with the paraformaldehyde solution for 20 min. After three
washings with water, the cells were stained with a 0.1% crystal
violet in 2% ethanol for 60 min. The wells were then washed again
with water in the dye was solubilised by using a 10% acetic acid
solution. The absorbance was measured at 570 nm using a plate
reader (Tecan, Lyon, France).
2.7 | Flow cytometry experiments
Cell cycle analyses were performed on undifferentiated or differ-
entiated podocytes treated or not with UFH (200 UI/ml, 48 hr) or
enoxaparin (200 UI/ml, 48 hr) or tinzaparin (200 UI/ml, 48 hr). After
treatment, cell monolayers were disrupted by trypsin–ethylenedia-
minetetraacetic acid treatment. The cells were then incubated with a
Hoescht solution (20 µM) for 30min at 37°C, washed and analysed
on a FACS Vantage cell sorter (BD Biosciences, San José, CA).
Specific ratings were done to determine the proportion of prolif-
erative and quiescent cells for each condition.
The detection of two parietal epithelial markers (Pax‐2 and
Claudin‐1) was performed on differentiated cells after their treat-
ments with UFH or enoxaparin or tinzaparin (200 UI/ml, 48 hr). The
cells were dissociated with trypsin and then fixed and permeabilised
by using paraformaldehyde (4% solution, 20min) and Triton X‐100
(0.2% solution, 20min), respectively. After washings, cells were
incubated with primary antibodies (1/100) directed against Pax‐2
(anti‐Pax‐2 antibody; Abcam) or against Claudin‐1 (Ozyme, Saint
Quentin en Yvelines, France) during 1 hr. Detection of the first
antibody was done by using anti‐rabbit Alexa Fluor 488 conjugated
secondary (1/200). The omission of the first antibody serves as a
negative control (background signal) for the acquisition on FACS
Vantage cell sorter.
2.8 | Evaluation of modulation of protein
expression by cell‐based immunoassay
Immunodetection of the proteins involved in cell–matrix interactions
were performed with antibodies directed against CD29 (integrin β1;
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Bio‐Rad, Marnes‐la‐Coquette, France), CD49c (integrin α3; Bio‐Rad),
CD61 (integrin β3; Bio‐Rad). Observation of expression of proteins
involved in intercellular interactions was done by using antibodies
directed against Nephrin (Sigma‐Aldrich, Saint‐Quentin Fallavier,
France) or ZO‐1 (BD Bioscience).
Differentiated podocytes grown in 96‐well plates were
treated or not with PAN (40 µg/ml), UFH (200 UI/ml), enoxaparin
(200 UI/ml) or tinzaparin (200 UI/ml) for 48 hr before to be
rapidly fixed and permeabilised with paraformaldheyde (4% in
PBS) and Triton X‐100 (0.2% in PBS), respectively. After
incubation with RPMI complete medium to block unspecific
binding sites, cells were incubated with the different antibodies
(1/100 in RPMI complete medium) for 3 hr. After several washes,
monoclonal antibodies binding was revealed with peroxidase‐
conjugated anti‐mouse antibodies (1/500; CliniSciences,
Nanterre, France) followed by 3,3′,5,5′‐tetramethylbenzidine
substrate. Optical density was quantified at 450 nm with a
spectrophotometer (Tecan). The omission of primary antibodies
served as control value that has been subtracted to the different
experimental points values.
2.9 | Statistical analysis
All results are expressed as means ± standard deviations (SD). Results
were compared using the nonparametric Mann–Whitney test. A
p < 0.05 (*) was considered statistically significant.
3 | RESULTS
3.1 | Effect of heparin and LMWH on podocyte
monolayer permeability
Initial experiments were done to analyse the effect of heparin,
enoxaparin, tinzaparin and fondaparinux on podocyte monolayer
permeability to fluorescent albumin. As shown in Figure 1a, heparin
was able to enhance the apparent permeability of albumin. The effect
was significant from a concentration of 50 UI/ml (p < 0.05) and the
permeability increased with heparin concentration. The apparent
permeability obtained with the highest concentration (400 UI/ml)
was in the same order as the value obtained with the nephrotoxic
drug PAN (Figure 1e). Similar data were obtained with enoxaparin
F IGURE 1 Effect of unfractionated
heparin and low molecular heparin
derivatives on podocyte permeability to
albumin. Differentiated podocytes grown
on permeable supports were incubated
with increasing concentrations of
unfractionated heparin (a), enoxaparin
(b), tinzaparin (c) or fondaparinux (d) for
48 hr before being tested for albumin
permeability. The nephrotoxic drug
puromycin aminonucleoside (PAN,
40 µg/ml) was used as a positive control of
podocyte perturbation (e). The results are
expressed as a mean ± SD of four
independent assays. Statistically significant
differences between untreated cells and
treated cells are calculated using the
nonparametric Mann–Whitney test
(*p < 0.05). BSA: bovine serum albumin
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(Figure 1b), but the effect was significant only from a concentration
of 200 UI/ml (p < 0.05). Similarly, an increase in enoxaparin concen-
tration was associated with an increase of albumin permeability. In
contrast to these results, tinzaparin (Figure 1c), fondaparinux
(Figure 1d), used in similar conditions, were unable to modulate
albumin permeability, suggesting relative specificity of this effect.
One should note that whatever the concentration used, no cell
toxicity could be observed using XTT and LDH assays (Supporting
Information Figure S1).
3.2 | Effect of direct oral anticoagulants on
podocyte permeability to albumin
Similar experiments were done with direct oral anticoagulants to
check if the effect observed could be related to the anticoagulant
properties of the compounds. After 48 hr of drug exposure, the
permeability to albumin was evaluated. The results, presented in
Figure 2, indicated that argatroban, dabigatran, or rivaroxaban were
unable to increase albumin permeability despite the use of relatively
high concentrations (Figure 2a–c). The use of PAN as a positive
control for podocyte alteration indicated that the cells were
nevertheless responsive. No cellular toxicity could be observed
whatever the condition (Supporting Information Figure S1).
3.3 | Analysis of morphological changes
Immunofluorescent experiments were then performed to analyse
potential cellular morphological changes after drug treatment. As
shown in Figure 3, the treatment of cells with UFH (Figure 3b) was
associated with a significant decrease in cell spreading (with the
presence of “hole areas”) compared with the control cells (untreated;
Figure 3a). The relatively homogeneous monolayer observed with
untreated cells was clearly disorganised after UFH treatment, with
cells displaying a compact morphology. This cellular shrinkage led to
uncoupling from adjacent cells. The actin filament labelling was
drastically modified and appeared concentrated around the nucleus,
reflecting an important cell condensation. Similar results were
obtained with enoxaparin treatment (Figure 3c), but this phenomen-
on was not observed for cells treated with tinzaparin (Figure 3d).
Furthermore, treatments of the cells with fondaparinux or with
argatroban did not show any podocyte morphological changes (data
not shown), in agreement with functional permeability tests.
3.4 | Cell surface evaluation under treatments
The visualisation of these cell morphological changes prompted us to
quantify the effects of UFH on cellular spreading and on cell
detachment. Differentiated podocytes were treated for 48 hr with
UFH (200 UI/ml) or with PAN (40 µg/ml) before to be incubated with
calcein to obtain a homogeneous labelling of the live cells. As shown
in Figure 4, the visualisation of the entire well demonstrated that the
monolayer was affected after PAN treatment with the presence of a
greater intercellular space compared with untreated monolayer. This
macroscopic observation was also noticed to a lesser extend after
heparin treatment. The observation at higher magnification clearly
confirmed the presence of “holes” between cells after puromycin
treatment. Cells treated with heparin also appeared slightly more
distant from each other than untreated cells. However, in these
conditions, the quantification of the number of cells, using ImageJ
software on 12 different pictures for each condition, did not evidence
F IGURE 2 Effect of direct oral
anticoagulants on podocyte permeability
to albumin. Podocytes were incubated with
different concentrations of dabigatran
(a), argatroban (b), or rivaroxaban (c) for
48 hr before being tested for albumin
permeability. Puromycin aminonucleoside
(PAN) served as positive control of
filtration alteration. The values are shown
as the mean ± SD of four independent tests.
Statistically significant differences
between untreated cells and treated cells
are calculated using the nonparametric
Mann–Whitney test (*p < 0.05).
BSA: bovine serum albumin
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significant differences between untreated or UFH treated cells. In
contrast, the surface of the cell monolayer and the surface of
individual cell were significantly lower (p < 0.005) for UFH treated
cells compared with untreated cells. This result indicated that UFH
treatment caused a “cell narrowing.” Similar quantifications were
performed on PAN treated cells. This drug, used as a positive control
for monolayer disturbance, was associated, as expected, with a
significant (p < 0.0001) decrease of the cell number compared with
untreated cells confirming the ability of this drug to promote
podocyte detachment. Accordingly, the total surface covered by
the cells was diminished. However, the individual cell surface was
also significantly decreased (p < 0.0001) indicating that the entire cell
surface decrease was not only he fact of cell loss but also due to a
narrowing of the individual cell surface.
In another experiment, the assessment of cellular detachment was
performed on PAN, UFH, enoxaparin and tinzaparin treated cells
(Supporting Information Figure S2). In contrast to the results mentioned
above, heparin treatment was associated with a significant cell loss
compared with untreated cells (67.9 ± 17% vs. 36.5 ± 15% of detached
cells for heparin and untreated cells, respectively). This result suggested
that heparin weakened cell adhesion. Interestingly, enoxaparin did not
affect significantly cell adhesion. The treatment with tinzaparin was quite
different since this drug seemed to limit cell loss compared with
untreated cells (9 ± 19% vs 36.5 ± 15%, respectively). As expected, PAN
treatment generated a significant cell detachment inducing more than
79% of cell loss.
3.5 | Dedifferentiation evaluation
As previously described (Delézay et al., 2017), undifferentiated
podocytes are smaller than differentiated ones that are spreading on
the culture support. The morphological changes observed with UFH‐
treated differentiated cells prompted us to analyse the effect of this
treatment on cellular dedifferentiation. Flow cytometry experiments
were performed with undifferentiated or differentiated podocytes
treated or not treated with UFH or enoxaparin or tinzaparin (200 UI/
ml, 48 hr). As demonstrated in Figure 5, heparin treatment was not
associated with a significant change in the cytograms obtained after
Hoescht cell labelling. As expected, the proportion of proliferative
cells was greater for undifferentiated podocytes than for differ-
entiated cells (34.6% vs. 18.9% of the total cell population,
respectively). After the different treatments, no significant increase
of proliferating cells could be noticed on differentiated cells. The
percentages were 22.4%, 21.8%, and 20.6% after heparin, enoxapar-
in, and tinzaparin treatments, respectively. These results suggested
that UFH or LMWH treatments were not associated with an increase
in proliferative capacity of the cells.
F IGURE 3 Morphological analysis of podocyte after treatment
with UFH and low molecular heparin derivatives. Differentiated
podocytes, grown on glass coverslips, were incubated or not (a) with
200 UI/ml of UFH (b), enoxaparin (c), or tinzaparin (d) for 48 hr
before being fixed and permeabilised. Phalloidin‐iFluor 555 was used
to visualise the F‐actin cytoskeleton component (in red) and DAPI
was used for nucleus labelling (in blue). Scale bar = 50 µm. DAPI: 4′,
6‐diamidine‐2′‐phenylindole dihydrochloride; UFH: unfractionated
heparin [Color figure can be viewed at wileyonlinelibrary.com]
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To confirm these results, the expression of Claudin‐1 and Pax‐2,
two markers of parietal epithelial cells, were analysed on differ-
entiated podocytes after the different treatments. The results
indicated that UFH, enoxaparin and tinzaparin (200 UI/ml, 48 hr)
did not modulate the expression of these two markers (Supporting
Information Figure S3) refuting the progression of these cells to a
parietal cell phenotype.
3.6 | Effect of heparin on α3β1 integrin, ZO‐1, and
nephrin expression
Intercellular contacts between podocytes and cell matrix attachment
are key elements for efficient glomerular filtration. ZO‐1, nephrin,
and the integrin α3β1 are, among a large panel of molecules, three
proteins needed for cell–cell interactions and cell–matrix adhesion,
respectively. Since UFH seems to modify the organisation of the
podocyte monolayer, the expression of ZO‐1 or α3β1 integrin or
nephrin was investigated on untreated or UFH treated cells by
immunofluorescent experiments. PAN treatment (40 µg/ml, 48 hr)
was used as control for podocyte morphological perturbation. As
shown in Figure 6, PAN treatment was associated with a modification
of α3β1 integrin distribution. The pattern was less homogeneous on
cell surface and appeared diminished compared with untreated cells.
Similar perturbations were evidenced for ZO‐1 expression with the
presence of rounded cells lacking ZO‐1 expression on their
cytoplasmic membrane. The detection of nephrin that display a
punctiform fluorescent labelling on untreated cells was also affected
with only few cells expressing this marker.
Heparin treatment (200 UI/ml, 48 hr) led also to a significant
decrease in α3β1 integrin labelling intensity. Compared with
untreated cells that displayed a homogeneous labelling on their
plasma membranes, the expression of the integrin on treated
cells was restricted to some parts of the plasma membrane or to
the intracellular compartment. Similar observation was obtained
with ZO‐1 labelling. The typical plasma membrane detection of
ZO‐1 observed with untreated cells was totally abolished, with
only few cells expressing ZO‐1 expression on their plasma
membrane. Nephrin was detected on heparin treated cells but
the signal was clearly lower and more heterogeneous than for
untreated cells.
(a) (b) (c)
F IGURE 4 Quantitative analysis of cell surface after UFH treatment. Podocytes, cultured in 24‐well plates, were treated with PAN
(40 µg/ml) or UFH (200 UI/ml) for 48 hr before to be labelled using calcein. Live cells were visualised using an epifluorescence inverted
microscope microscope (IX81; Olympus, Tokyo, Japan) allowing the observation of the entire well by using a FITC filter for observing calcein‐
AM labelling. For each condition, 12 pictures were randomly captured and analysed for cell number (a), total (b), or individual (c) cell surface.
Statistically significant differences between the different conditions were estimated using the nonparametric Mann–Whitney test
(***p < 0.0005; **p < 0.005). FITC: fluorescein isothiocyanate; ns: not significant; PAN: puromycin aminonucleoside; UFH: unfractionated heparin
[Color figure can be viewed at wileyonlinelibrary.com]
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3.7 | Quantification of integrins, nephrin and ZO‐1
expression by cell‐based immunoassays
To quantify the variation observed in immunofluorescence experi-
ments, a semiquantitative cell‐based immunoassay was performed on
untreated cells or cells treated with UFH (200 UI/ml), enoxaparin
(200 UI/ml) or tinzaparin (200 UI/ml) for 48 hr. As illustrated in
Figure 7, all the proteins tested were significantly decreased by UFH
treatment compared with untreated cells. Similar effects were
observed with enoxaparin, except for CD61 (integrin β3) expression
which was not significantly modified. The most pronounced effect of
UFH was observed for the expressions of nephrin and ZO‐1, that
were diminished by 41% and 45%, respectively, compared with
control cells. The expression of the β1 (CD29) and α3 (CD49c)
integrins were also affected and decreased by 22% and 32%,
respectively, compared with the untreated cells. The effect of
enoxaparin displayed a similar profile with a significant decrease in
nephrin and ZO‐1 expressions (−44% and −48% in comparison to
untreated cells, respectively). Interestingly, the effect of tinzaparin
was very different with ZO‐1 expression slightly diminished (−17%
compared with untreated cells). The expressions of the markers
CD29 and nephrin were not modified. In contrast, α3 (CD49c) and
β3 (CD61) were increased compared with untreated cells (+7% and
+33%, respectively). These results confirmed that enoxaparin and
tinzaparin act differently on podocytes. PAN treatment, used as
control, significantly diminished the expression of the different
markers tested (Supporting Information Figure S4).
4 | DISCUSSION
UFH and LMWH have long been used for the prevention or
treatment of thrombotic events and are more recently studied for
their nonanticoagulant properties such as anti‐inflammatory, anti-
angiogenic, or antimetastatic effects (Yan et al., 2017). These new
properties offer interesting perspectives but need the evaluation of
these compounds on specific target cells to explore their potential
beneficial or deleterious effects. The fact that these drugs are mainly
excreted by the kidney prompted us to explore their effects on
podocyte, a major actor of the glomerular filtration.
We analysed the effect of UFH or LMWH on podocyte monolayer
permeability by using an in vitro human podocyte model allowing a
functional test combined with morphological/phenotypic analysis.
F IGURE 5 Flow cytometry study of
podocyte replication properties after
unfractionated heparin (UFH) or low
molecular heparin derivative (LMWH)
treatments. Undifferentiated (a) and
differentiated (b–e) podocytes were grown
in 25 cm2 flasks and treated or not with
200 UI/ml of UFH (c) or enoxaparin (d) or
tinzaparin (e) for 48 hr before monolayer
disruption and cell incubation with
Hoescht solution (20 µM, 30min, 37°C).
Cell cycle analysis was performed on a
fluorescence‐activated cell sorting (FACS)
Vantage cell sorter (BD Biosciences, San
José, CA). P4 and P5 gating allowed the
quantification of quiescent or replicative
cells, respectively
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Our data demonstrated that UFH and enoxaparin were able to
increase the permeability of podocytes to albumin in contrast to
tinzaparin or fondaparinux or direct oral anticoagulants. The effect
was not associated with cell toxicity as evidenced by LDH or XTT
assays, despite a high range of concentrations (in agreement with the
results obtained by Yaoita et al.). Immunofluorescent studies
revealed that the deleterious effect on podocyte permeability was
correlated with morphological perturbations and phenotypic
changes. Quantification of cell number and cell surface parameters
indicated that UFH caused a cellular shrinking. UFH weakened cell
adhesion as evidenced in detachment assay experiment. Finally, cell‐
based immunoassay experiments demonstrated that UFH and
enoxaparin only were able to decrease the expression of proteins
involved in podocyte adhesion or in cell–cell interactions.
In accordance with previous results (Delézay et al., 2017), this study
confirmed that UFH increases the permeability of albumin through a
podocyte monolayer. This effect correlated with the concentration of
UFH with an apparent permeability of albumin reaching the values
obtained with the nephrotoxic drug PAN. Similar data were obtained
with enoxaparin. Interestingly, tinzaparin or fondaparinux had no effect
on podocyte permeability. This first result indicated that enoxaparin and
tinzaparin, both derived from UFH, do not possess the same biological
activity on these glomerular epithelial cells. This result also suggested
that this effect was not directly associated with the anticoagulant
property of the molecule. This point is furthermore reinforced by the
use of another class of molecules (direct oral anticoagulant compounds)
that are unable to modulate albumin permeability in our in vitro model.
The discrepancy observed between enoxaparin and tinzaparin effects
on podocyte filtration function may be due to different manufacturing
processes. Tinzaparin is the only heparin derivative that is obtained by
an enzymatic digestion (heparanase); while enoxaparin is obtained after
benzylation and alkaline depolymerisation of heparin. Therefore, the
two drugs possess different physicochemical properties, such as a
different molecular weight distribution (Bisio et al., 2015) or sulfation.
The proportion of low molecular weight polysaccharides (<2,000Da) is
greater for enoxaparin (12–20%) than for tinzaparin (<10%). These
considerations could explain the differences observed in our functional
test and could be compared with those obtained by Bârzu et al. (1986)
on endothelial cells. In the same way, tinzaparin and enoxaparin
displayed different antiangiogenic properties (Mousa, 2013) or different
antifibrotic effects in the liver (Abdel‐Salam, Baiuomy, Ameen, &
Hassan, 2005) for example. The fact that the effect observed on
podocyte permeability is only obtained at high concentrations, far from
the concentrations used in clinical use, may suggests that the “active
molecule(s)” is (are) probably present in small amounts in the
heterogeneous mixtures of heparin and enoxaparin.
The particular organisation of podocyte monolayer is a key
element for an efficient glomerular filtration. Then, we have analysed
morphological and phenotypic changes that could be induced by UFH
or LMWH treatments.
F IGURE 6 Modulation of the expression of nephrin, α3β1 integrin, and ZO‐1 by PAN or UFH treatment. Differentiated podocytes, grown on
glass coverslips, were treated or not with UFH (200 UI/ml, 48 hr) or with PAN (40 µg/ml) before being fixed and permeabilised. Cells were
incubated with antibodies directed against nephrin, α3β1 integrin, or ZO‐1, which were revealed (in green) by using Alexa Fluor 488 conjugated
goat anti‐mouse IgG antibodies. Nucleus staining was performed with DAPI (in blue). Omission of the primary antibody served as negative
control. Scale bar = 20 µm. DAPI: 4′,6‐diamidino‐2‐phenylindole; IgG: immunoglobulin G; PAN: puromycin aminonucleoside;
UFH: unfractionated heparin [Color figure can be viewed at wileyonlinelibrary.com]
DELÉZAY ET AL. | 9
Immunofluorescent experiments demonstrated that enoxaparin and
UFH (but not tinzaparin, fondaprinux or argatroban) treatments were
able to modify cellular morphology. In particular, the actin fibres
(visualised by using fluorescent phalloidin) appeared clearly condensed
compared with untreated cells, indicating that the treatment of the
podocytes with the two drugs provoked an alteration of the cell
cytoskeleton. The podocyte cytoskeleton is a key for efficient
glomerular filtration (Welsh & Saleem, 2011) and this result can explain
the increase in permeability to albumin observed in our functional
assays after UFH and enoxaparin treatments. Other immunofluorescent
experiments demonstrated a decrease in expression of α3β1 integrin,
nephrin and ZO‐1 proteins after UFH treatment, proteins that are
critical for the adhesion of podocytes to the glomerular basement
membrane (Chen et al., 2006; Pozzi et al., 2008) or intercellular
interactions. These contacts, between the elongated interdigitating foot
processes, are assured by specific proteins such as nephrin, ZO‐1 and
podocin, which are closely associated with the cell cytoskeleton (Conti,
Perico, Grahammer, & Huber, 2017). The decrease in expression of
α3β1 integrin combined with the downregulation of ZO‐1 and nephrin
may explain the alteration in cellular morphology observed after UFH
treatment, leading to larger monolayer permeability. The quantification
of cell surface revealed that UFH treatment generated a significant
cellular shrinking. This effect is comparable to that obtained after
puromycin aminonucleoside treatment of the cells, although the latter is
much more important. The analysis of cell adhesion confirms that UFH
treatment weakens cell attachment. This cell condensation, enhancing
the intercellular spaces, associated with cell loss is probably the main
cause of podocyte permeability increase after heparin treatment.
Confirming immunofluorescent experiments, we found that the
treatment of podocytes with UFH or enoxaparin resulted in a
significant quantitative decrease in ZO‐1, α3 and β1 markers and was
also responsible for a decrease in β3 and nephrin proteins. Tinzaparin
did not significantly modify the expression of nephrin and induced
only a moderate decrease in ZO‐1 expression. In addition, conversely
to the effect obtained with UFH or enoxaparin, tinzaparin increased
the expression of α3 and β3 markers. This last point can explain the
fact that tinzaparin significantly enhances cell adhesion as evidenced
in cellular detachment assays results. In addition, these data highlight
different or even opposite effects of these products, which may
explain the differences observed in the functional tests.
Taken together, our data indicate that UFH and enoxaparin
perturb podocyte filtration property, probably by modifying the
cytoskeleton and/or decreasing the expression of specific proteins
involved in podocyte attachment and cell–cell interactions inducing a
the decrease of the cellular spreading. This is not the case with
tinzaparin. However, it is quite difficult to distinguish the chron-
ological and the relative part of these two events in the perturbation
of the podocyte permeability. Considering that glomerular filtration
does not involve only podocytes but is also dependent on endothelial
cells as well as a glomerular basement membrane, the evaluation of
the effects of UFH and LMWH on a more complex in vitro system
including these two parameters will be of particular relevance.
The intracellular mechanisms leading to podocyte injury by UFH or
enoxaparin remain to be elucidated. A potential lead is the intracellular
calcium path, since the podocyte cytoskeleton is highly sensitive to
intracellular calcium modulations (Greka & Mundel, 2012). This
hypothesis is supported by the fact that heparin can inhibit IP3‐induced
Ca2+ release (Nilsson, Zwiller, Boynton, & Berggren, 1988) and interfere
with SDF‐1 binding to CXCR4 (Ma et al., 2012), limiting the increase of
intracellular concentration of calcium induced by SDF‐1.
Finally, our study demonstrated that UFH and enoxaparin can
deregulate podocyte permeability. Furthermore, our data indicate
that the different LMWHs possess specific biological nonanticoagu-
lant effects, depending on the manufacturing process involved in the
elaboration of the drug. This new property, unrelated to the
anticoagulant effect of these products, confirms that in vitro tests
represent interesting tools for the evaluation of new biological
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F IGURE 7 Effect of (UFH or low molecular heparin derivatives on
protein expression revealed by a cell‐based immunoassay.
Differentiated podocytes, cultured in 96‐well plates, were treated or
not with 200 UI/ml of UFH or enoxaparin or tinzaparin for 2 d. After
the fixation and permeabilisation steps, cells were incubated with the
specified antibodies that were revealed with HRP‐conjugated
anti‐mouse antibodies and 3,3′,5,5′‐tetramethylbenzidine as
substrate. Optical density (absorbance) measurements were
performed with a spectrophotometer (450 nm). Values reported are
the mean ± SD of six independent assays. *p < 0.05, **p < 0.01,
(p > 0.05). HRP: horseradish peroxidase; ns: not significant;
UFH: unfractionated heparin
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properties of LMWH. Our in vitro system, allowing functional and
morphological approaches, could be used for the screening of several
drugs that can interact with the podocyte.
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